Aktis Oncology, Inc. (AKTS)
NASDAQ: AKTS · Real-Time Price · USD
23.30
-0.64 (-2.67%)
Sep 11, 2026, 4:00 PM EDT - Market closed
Aktis Oncology Revenue
Aktis Oncology had revenue of $3.38M in the quarter ending June 30, 2026, with 133.86% growth. This brings the company's revenue in the last twelve months to $10.06M, up 576.53% year-over-year. In the year 2025, Aktis Oncology had annual revenue of $6.50M with 336.92% growth.
Revenue (ttm)
$10.06M
Revenue Growth
+576.53%
P/S Ratio
128.82
Revenue / Employee
$127,342
Employees
79
Market Cap
1.30B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 6.50M | 5.01M | 336.92% |
| Dec 31, 2024 | 1.49M | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
AKTS News
- 4 days ago - Oppenheimer bullish on Aktis Oncology, initiates with an Outperform - TheFly
- 4 days ago - Aktis Oncology initiated with an Outperform at Oppenheimer - TheFly
- 25 days ago - Wedbush starts Aktis Oncology at Outperform on radiopharma potential - TheFly
- 25 days ago - Aktis Oncology initiated with an Outperform at Wedbush - TheFly
- 25 days ago - BMO starts Aktis at Outperform, says opportunities not captured in valuation - TheFly
- 25 days ago - Aktis Oncology initiated with an Outperform at BMO Capital - TheFly
- 4 weeks ago - Aktis Oncology reports Q2 revenue $3.38M, consensus $2.58M - TheFly
- 4 weeks ago - Bank of America Sees Bargains in These 16 Knocked-Down AI Stocks - Investopedia